NASDAQ:QDEL

QuidelOrtho - QDEL Stock Forecast, Price & News

$86.14

-1.60 (-1.82%)

(As of 08/19/2022 03:46 PM ET)

Add

Compare

Today's Range: $85.46
▼
$87.43
50-Day Range: $84.09
▼
$107.63
52-Week Range: $83.39
▼
$180.06

Volume: 16,451 shs
Average Volume: 783,452 shs
Market Capitalization: $5.77 billion

P/E Ratio: 3.65
Dividend Yield: N/A
Price Target: $98.67

QuidelOrtho MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 14.4% Upside
$98.67 Price Target
Short Interest: Bearish
4.65% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.61
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -54.57%
From $11.60 to $5.27 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

833rd out of 1,119 stocks

Diagnostic Substances Industry

10th out of 17 stocks

2.2

Analyst's Opinion

Consensus Rating
QuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $98.67, QuidelOrtho has a forecasted upside of 14.4% from its current price of $86.24.
Amount of Analyst Coverage
QuidelOrtho has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.65% of the outstanding shares of QuidelOrtho have been sold short.
Short Interest Ratio / Days to Cover
QuidelOrtho has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in QuidelOrtho has recently increased by 25.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
QuidelOrtho does not currently pay a dividend.
Dividend Growth
QuidelOrtho does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
QuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.
Environmental Sustainability
The Environmental Impact score for QuidelOrtho is -2.61.

3.1

News and Social Media Coverage

News Sentiment
QuidelOrtho has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for QuidelOrtho this week, compared to 6 articles on an average week.
Search Interest
14 people have searched for QDEL on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.
MarketBeat Follows
15 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, QuidelOrtho insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.70% of the stock of QuidelOrtho is held by insiders.
Percentage Held by Institutions
92.89% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for QuidelOrtho are expected to decrease by -54.57% in the coming year, from $11.60 to $5.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of QuidelOrtho is 3.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of QuidelOrtho is 3.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.74.
Price to Book Value per Share Ratio
QuidelOrtho has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About QuidelOrtho (NASDAQ:QDEL) Stock

QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company's product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products. The company was founded in 1979 and is headquartered in San Diego, California.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on QDEL shares. UBS Group started coverage on shares of QuidelOrtho in a research report on Wednesday, July 20th. They set a "sell" rating and a $86.00 target price for the company. StockNews.com cut QuidelOrtho from a "buy" rating to a "hold" rating in a report on Monday. Finally, JPMorgan Chase & Co. initiated coverage on QuidelOrtho in a report on Friday, June 17th. They set a "neutral" rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $98.67.

QuidelOrtho Stock Down 1.9 %

Shares of QDEL traded down $1.67 during trading hours on Friday, reaching $86.07. The stock had a trading volume of 13,463 shares, compared to its average volume of 783,452. QuidelOrtho has a 12 month low of $83.39 and a 12 month high of $180.06. The firm has a 50-day simple moving average of $98.50 and a 200 day simple moving average of $101.54. The company has a current ratio of 1.73, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $5.76 billion, a price-to-earnings ratio of 3.64 and a beta of 0.03.

Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

QDEL Stock News Headlines

August 18, 2022 | seekingalpha.com

QuidelOrtho announces $300M share repurchase authorization - Seeking Alpha

August 17, 2022 | businesswire.com

QuidelOrtho Announces $300 Million Share Repurchase Authorization - Business Wire

August 17, 2022 | finance.yahoo.com

QuidelOrtho Announces $300 Million Share Repurchase Authorization

August 16, 2022 | nasdaq.com

Analysts Forecast 13% Gains Ahead For The Holdings of AFMC - Nasdaq

August 16, 2022 | americanbankingnews.com

QuidelOrtho (NASDAQ:QDEL) Downgraded to Hold at StockNews.com

August 14, 2022 | americanbankingnews.com

Analyzing QuidelOrtho (NASDAQ:QDEL) & Navidea Biopharmaceuticals (NYSE:NAVB)

August 12, 2022 | finance.yahoo.com

What You Need To Know About QuidelOrtho Corporation's (NASDAQ:QDEL) Investor Composition

August 11, 2022 | usatoday.com

Want to be sure you don't have COVID? FDA now says you'll need to pass 3 home tests - USA TODAY

August 10, 2022 | forbes.com

Down 15% In A Month, Will QuidelOrtho Stock Rebound?

August 9, 2022 | fool.com

QuidelOrtho (QDEL) Q2 2022 Earnings Call Transcript - The Motley Fool

August 9, 2022 | finance.yahoo.com

QuidelOrtho (QDEL) Q2 2022 Earnings Call Transcript

August 9, 2022 | seekingalpha.com

The Market Doesn't Believe QuidelOrtho's Good Fortune (NASDAQ:QDEL) - Seeking Alpha

August 6, 2022 | seekingalpha.com

QuidelOrtho falls 6% on Q2 result miss (NASDAQ:QDEL) - Seeking Alpha

August 5, 2022 | apnews.com

QuidelOrtho: Q2 Earnings Snapshot

August 5, 2022 | seekingalpha.com

QuidelOrtho Corporation (QDEL) CEO Douglas Bryant on Q2 2022 - Earnings Call Transcript

August 5, 2022 | nasdaq.com

QuidelOrtho (QDEL) Q2 Earnings Miss Estimates

August 5, 2022 | finance.yahoo.com

QuidelOrtho Reports Second Quarter 2022 Financial Results - Yahoo Finance

August 4, 2022 | businesswire.com

QuidelOrtho Reports Second Quarter 2022 Financial Results - Business Wire

August 4, 2022 | finance.yahoo.com

QuidelOrtho Reports Second Quarter 2022 Financial Results

August 3, 2022 | americanbankingnews.com

QuidelOrtho (QDEL) Scheduled to Post Earnings on Thursday

July 29, 2022 | nasdaq.com

What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings? - Nasdaq

July 28, 2022 | finance.yahoo.com

Laboratory Industry Doesn't Forget COVID-19, But Shifts Focus to Other Health Conditions at AACC 2022 in Chicago - Yahoo Finance

July 27, 2022 | finance.yahoo.com

QuidelOrtho Corporation (NASDAQ:QDEL) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

July 26, 2022 | finance.yahoo.com

ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW

July 26, 2022 | nasdaq.com

Cal-Maine Foods, Inc. (NASDAQ:CALM) Is About To Go Ex-Dividend, And It Pays A 0.9% Yield - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

QDEL Company Calendar

Last Earnings: 11/04/2021
Today: 8/19/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:QDEL
CUSIP: 74838J10
CIK: 353569
Web: www.quidel.com
Phone: (858) 552-1100
Fax: 858-453-4338
Employees: 1,600
Year Founded: 1979

Price Target and Rating

Average Stock Price Forecast: $98.67
High Stock Price Forecast: $130.00
Low Stock Price Forecast: $80.00
Forecasted Upside/Downside: +14.5%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $23.60
Trailing P/E Ratio: 3.65
Forward P/E Ratio: 7.43
P/E Growth: N/A
Net Income: $704.23 million
Net Margins: 36.43%
Pretax Margin: 47.80%
Return on Equity: 42.55%
Return on Assets: 28.18%

Debt

Debt-to-Equity Ratio: 0.51
Current Ratio: 1.73
Quick Ratio: 1.12

Sales & Book Value

Annual Sales: $1.70 billion
Price / Sales: 3.40
Cash Flow: $19.27 per share
Price / Cash Flow: 4.47
Book Value: $73.48 per share
Price / Book: 1.17

Miscellaneous

Outstanding Shares: 66,950,000
Free Float: 65,145,000
Market Cap: $5.77 billion
Optionable: Optionable
Beta: 0.03

Social Links

Key Executives

Mr. Douglas C. Bryant (Age 64)
Chairman & CEO
Comp: $1.41M

Mr. Robert J. Bujarski J.D. (Age 53)
Pres & COO
Comp: $770.62k

Ms. Michelle A. Hodges (Age 62)
Gen. Counsel
Comp: $620.61k

Dr. Werner Kroll Ph.D. (Age 65)
Sr. VP of R&D
Comp: $758.22k

Mr. Joseph M. Busky CPA (Age 54)
Chief Financial Officer

Ruben Argueta
Director of Investor Relations

Mr. Michael S. Iskra (Age 52)
Chief Commercial Officer

Phillip S. Askim
VP, Associate Gen. Counsel & Sec.

Dr. Johannes Kehle
Pres of AnDiaTec Division

Mr. Rhys de Callier
VP of Strategy & Portfolio Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

QDEL Stock - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 1 sell rating, 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares.
View QDEL analyst ratings or view top-rated stocks.
What is QuidelOrtho's stock price forecast for 2022?: 3 Wall Street research analysts have issued 1 year target prices for QuidelOrtho's shares. Their QDEL share price forecasts range from $80.00 to $130.00. On average, they expect the company's stock price to reach $98.67 in the next twelve months. This suggests a possible upside of 12.5% from the stock's current price.
View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts.
How have QDEL shares performed in 2022?: QuidelOrtho's stock was trading at $134.99 at the start of the year. Since then, QDEL shares have decreased by 35.0% and is now trading at $87.74.
View the best growth stocks for 2022 here.
When is QuidelOrtho's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our QDEL earnings forecast.
How were QuidelOrtho's earnings last quarter?: QuidelOrtho Co. (NASDAQ:QDEL) posted its earnings results on Thursday, November, 4th. The company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $3.52 by $1.84. The company had revenue of $509.70 million for the quarter, compared to the consensus estimate of $344.25 million. QuidelOrtho had a net margin of 36.43% and a trailing twelve-month return on equity of 42.55%. QuidelOrtho's revenue was up 7.1% on a year-over-year basis. During the same period in the prior year, the firm earned $5.68 EPS.
What guidance has QuidelOrtho issued on next quarter's earnings?: QuidelOrtho issued an update on its FY 2022 earnings guidance on Friday, August, 19th. The company provided earnings per share guidance of $11.80-$12.75 for the period. The company issued revenue guidance of $3.78 billion-$3.91 billion, compared to the consensus revenue estimate of $2.83 billion.
What is Doug Bryant's approval rating as QuidelOrtho's CEO?: 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees.

What other stocks do shareholders of QuidelOrtho own?: Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).
What is QuidelOrtho's stock symbol?: QuidelOrtho trades on the NASDAQ under the ticker symbol "QDEL."
Who are QuidelOrtho's major shareholders?: QuidelOrtho's stock is owned by many different retail and institutional investors. Top institutional investors include Carlyle Group Inc. (29.77%), Price T Rowe Associates Inc. MD (11.42%), State Street Corp (2.09%), JPMorgan Chase & Co. (2.07%), AQR Capital Management LLC (1.24%) and Massachusetts Financial Services Co. MA (1.07%). Insiders that own company stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Edward L Michael, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Matthew Strobeck, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Werner Kroll, William J Ferenczy and William J Ferenczy.
View institutional ownership trends.
How do I buy shares of QuidelOrtho?: Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is QuidelOrtho's stock price today?: One share of QDEL stock can currently be purchased for approximately $87.74.
How much money does QuidelOrtho make?: QuidelOrtho (NASDAQ:QDEL) has a market capitalization of $5.87 billion and generates $1.70 billion in revenue each year. The company earns $704.23 million in net income (profit) each year or $23.60 on an earnings per share basis.
How many employees does QuidelOrtho have?: The company employs 1,600 workers across the globe.
When was QuidelOrtho founded?: QuidelOrtho was founded in 1979.
How can I contact QuidelOrtho?: QuidelOrtho's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The official website for the company is www.quidel.com. The company can be reached via phone at (858) 552-1100, via email at rargueta@quidel.com, or via fax at 858-453-4338.

This page (NASDAQ:QDEL) was last updated on 8/19/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

QuidelOrtho - QDEL Stock Forecast, Price & News

QuidelOrtho MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability